Dennis Mulroy - 01 May 2026 Form 4 Insider Report for Arcturus Therapeutics Holdings Inc. (ARCT)

Reporting relationship: Chief Financial Officer
Issuer ticker: ARCT
Reported as of: 01 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 May 2026, 16:32:54 UTC
Prior SEC filing: 09 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Grant Levine, as attorney-in-fact for Dennis Mulroy

Key filing fact

Dennis Mulroy filed Form 4 for Arcturus Therapeutics Holdings Inc. (ARCT) on 07 May 2026.

Key facts

This page summarizes Dennis Mulroy's Form 4 filing for Arcturus Therapeutics Holdings Inc. (ARCT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 May 2026, 16:32.

Change

Previous filing in this sequence was filed on 09 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001276840 Primary reporting owner

MULROY DENNIS

Relationship: Chief Financial Officer
Address: C/O ARCTURUS THERAPEUTICS HOLDINGS INC., 10285 SCIENCE CENTER DRIVE, SAN DIEGO
Signature: /s/ Grant Levine, as attorney-in-fact for Dennis Mulroy
Signature date: 07 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARCT transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +100,000
Change %
Price: $0.000000^*
Shares after: 100,000
Date: 01 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $8.63
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

Footnote F2

The shares underlying this option vest 25% on May 1, 2027, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.